Taysha Gene Therapies, Inc. (TSHA)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.35B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,673,220
- 52-week high
- —
- 52-week low
- —
- Open
- $5.95
- Day high
- $6.05
- Day low
- $5.57
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $9.77M | -$109M | -$0.34 |
| 2024 | $8.33M | -$89.3M | -$0.36 |
| 2023 | $15.45M | -$111.57M | -$0.96 |
| 2022 | $2.5M | -$166.01M | -$3.78 |
| 2021 | — | -$174.52M | -$4.64 |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
- CEO
- Sean Nolan
- Employees
- 99
- Country
- US
- IPO date
- Sep 24, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Taysha Gene Therapies, Inc.'s stock price today?
- TSHA is trading at $5.58 as of Jul 20, 2026.
- What is Taysha Gene Therapies, Inc.'s market cap?
- Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.35B.
- Does Taysha Gene Therapies, Inc. pay a dividend?
- Taysha Gene Therapies, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Taysha Gene Therapies, Inc. in?
- Taysha Gene Therapies, Inc. operates in the Healthcare sector.